Latest Biotech News

Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to accelerate large‑scale AI models for protein design, the company said. Profluent will expand its...

Tel Aviv‑based Cassidy Bio closed an $8 million seed round led by Ahren Innovation Capital to develop an AI platform that predicts optimal combinations of guide RNAs, enzymes and delivery...

GSK and Flagship Pioneering revealed the first company‑specific deals under their multi‑platform collaboration: Profound Therapeutics will apply its ProFoundry proteomics platform and Quotient...

Tessera Therapeutics confirmed an imminent start to its first‑in‑human trial of an in‑vivo gene‑writing platform, enrolling adults with a rare genetic disease. The move marks a key inflection...

Abbott announced a definitive agreement to acquire Exact Sciences in a cash deal valued at roughly $21–23 billion, paying $105 per share and folding Exact’s cancer‑screening portfolio into...

The U.S. Food and Drug Administration granted approval to Bayer’s oral HER2‑directed therapy Hyrnuo (sevabertinib) for adults with locally advanced or metastatic non‑squamous NSCLC harboring...

Contineum Therapeutics reported topline Phase 2 VISTA results showing PIPE‑307, an M1 receptor antagonist developed with Janssen (J&J), failed to meet its primary efficacy endpoint of improving...

The Centers for Disease Control and Prevention revised vaccine safety language on its website to state the claim that vaccines do not cause autism is “not an evidence‑based claim” and that studies...

Function Health raised $298 million in a Series B round led by Redpoint Ventures, propelling the lab‑testing startup to a $2.5 billion valuation. The Austin‑based company provides consumer and...

Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to expand AI‑driven protein design capabilities. The Emeryville company said it will deploy the capital to...

Aspen Neuroscience secured $115 million in Series C financing to support its personalized autologous cell therapy program for Parkinson’s disease and to expand manufacturing capacity. The funding...

GSK signed early‑stage discovery agreements with Flagship Pioneering portfolio companies Profound Therapeutics and Quotient Therapeutics, validating proteomic and somatic‑genomics platforms for...

Researchers from David Liu’s group at the Broad Institute published a new prime editing‑based strategy, PERT (prime editing‑installed suppressor tRNAs), that converts endogenous tRNAs into...

Tessera Therapeutics confirmed it will start the first human trial of its in vivo gene‑writing platform next month, targeting an adult population with a rare genetic disorder. The move marks the...

Abbott announced a definitive agreement to acquire Exact Sciences for $105 per share, valuing the cancer-diagnostics company at roughly $21 billion. The acquisition brings Cologuard, Oncotype DX,...

The U.S. Food and Drug Administration granted accelerated approval to Bayer’s oral HER2-directed therapy Hyrnuo (sevabertinib) for adults with advanced non–small-cell lung cancer harboring...

The Centers for Disease Control and Prevention revised a vaccine-safety webpage to state that a causal link between vaccines and autism cannot be entirely ruled out — a marked change from the...

Function Health closed a $298 million Series B round that values the lab-testing startup at $2.5 billion and underscores investor demand for consumer-facing diagnostics platforms. The Austin-based...

Moderna secured $1.5 billion in financing to support its strategic pivot toward seasonal vaccines, oncology and rare disease programs and to help drive the company to breakeven in coming years....

Hepta, founded by former Grail scientists, released proof-of-concept data showing that cfDNA methylation patterns reflect liver disease biology, including fibrosis, and correlate with single-cell...